长风药业(02652)奥洛他定莫米松鼻喷雾剂临床试验申请获NMPA批准

智通财经网03-09

智通财经APP讯，长风药业(02652)发布公告，奥洛他定莫米松鼻喷雾剂的临床试验申请(CTA)已获中华人民共和国国家药品监督管理局(NMPA)批准。公司是中国首家就该产品提交仿制药临床试验申请的企业。该CTA的获批标志着推进该产品进入临床试验阶段的里程碑。开发固定剂量复方鼻喷雾剂面临重大的技术挑战，特别是在制剂稳定性、悬浮系统、喷雾一致性及规模化生产方面。该产品的进展进一步印证了集团在复杂鼻喷雾...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2618469288?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-09 07:48","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2618469288","market":"fut","top_or_hot":-1,"title":"长风药业(02652)奥洛他定莫米松鼻喷雾剂临床试验申请获NMPA批准","media":"智通财经网","content":"<div>\n<p>智通财经APP讯，长风药业(02652)发布公告，奥洛他定莫米松鼻喷雾剂的临床试验申请(CTA)已获中华人民共和国国家药品监督管理局(NMPA)批准。公司是中国首家就该产品提交仿制药临床试验申请的企业。该CTA的获批标志着推进该产品进入临床试验阶段的里程碑。开发固定剂量复方鼻喷雾剂面临重大的技术挑战，特别是在制剂稳定性、悬浮系统、喷雾一致性及规模化生产方面。该产品的进展进一步印证了集团在复杂鼻喷雾...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1411361.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>长风药业(02652)奥洛他定莫米松鼻喷雾剂临床试验申请获NMPA批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n长风药业(02652)奥洛他定莫米松鼻喷雾剂临床试验申请获NMPA批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-09 07:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1411361.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，长风药业(02652)发布公告，奥洛他定莫米松鼻喷雾剂的临床试验申请(CTA)已获中华人民共和国国家药品监督管理局(NMPA)批准。公司是中国首家就该产品提交仿制药临床试验申请的企业。该CTA的获批标志着推进该产品进入临床试验阶段的里程碑。开发固定剂量复方鼻喷雾剂面临重大的技术挑战，特别是在制剂稳定性、悬浮系统、喷雾一致性及规模化生产方面。该产品的进展进一步印证了集团在复杂鼻喷雾...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1411361.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1411361.html","article_id":"2618469288","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618469288","pubTimestamp":1773013699,"columns":[],"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，长风药业 发布公告，奥洛他定莫米松鼻喷雾剂的临床试验申请已获中华人民共和国国家药品监督管理局批准。公司是中国首家就该产品提交仿制药临床试验申请的企业。该CTA的获批标志着推进该产品进入临床试验阶段的里程碑。该产品的进展进一步印证了集团在复杂鼻喷雾制剂及药械整合方面的执行能力。集团将与NMPA保持积极沟通，并按照监管要求推进后续临床活动。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1191":"制药","02652":"长风药业"},"translate_title":"Changfeng Pharmaceutical (02652) Olopatadine Mometasone Nasal Spray Clinical Trial Application Approved by NMPA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02652":1.5},"content_text":"智通财经APP讯，长风药业(02652)发布公告，奥洛他定莫米松鼻喷雾剂的临床试验申请(CTA)已获中华人民共和国国家药品监督管理局(NMPA)批准。公司是中国首家就该产品提交仿制药临床试验申请的企业。该CTA的获批标志着推进该产品进入临床试验阶段的里程碑。开发固定剂量复方鼻喷雾剂面临重大的技术挑战，特别是在制剂稳定性、悬浮系统、喷雾一致性及规模化生产方面。该产品的进展进一步印证了集团在复杂鼻喷雾制剂及药械整合方面的执行能力。此外，该产品与集团现有的过敏性鼻炎(AR)及慢性鼻窦炎(CRS)产品组合形成互补，目前该组合包括氮䓬斯汀氟替卡松鼻喷雾剂(舒霏敏®)、糠酸莫米松鼻喷雾剂及布地奈德鼻喷雾剂。该产品组合覆盖了广泛的年龄层及疾病阶段，为上唿吸道疾病提供可及的长期管理方案。公司相信，其在复杂制剂与精准给药方面的综合能力将持续强化其在国内及全球市场的竞争优势。集团将与NMPA保持积极沟通，并按照监管要求推进后续临床活动。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618469288","isCrawlerRequest":true}